CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 2015—The Binding Site, through its arrangement with Arotec Diagnostics, offers an Ro (SSA) antigen designed for use as a component in solid phase ELISA-based immunoassay test procedures for the detection of anti-Ro (SSA) antibodies for use in research and in vitro diagnostic manufacturing applications.
Antibodies to the Ro (SSA) antigen are frequent serological markers of autoimmunity in rheumatic diseases. These autoantibodies are typically present in the serum of 50 to 80 percent of patients with Sjögren’s syndrome, 30 to 40 percent of patients with systemic lupus erythematosus, and three to five percent of patients with rheumatoid arthritis. Ro (SSA) autoantibodies have also been reported to be present in primary biliary cirrhosis, progressive systemic sclerosis, polymyositis, multiple myeloma, neonatal lupus syndrome, and other lupus-associated disorders including subacute cutaneous lupus erythematosus, Sjögren’s syndrome-lupus overlap disease, and lupus with complement component deficiencies.
Extracted and purified from bovine thymus of New Zealand origin, the Ro (SSA) antigen exhibits a level of purity greater than 90 percent, as assessed by SDS polyacrylamide gel electrophoresis, while demonstrating exceptional degrees of activity and specificity. The product aims to offer exceptional lot-to-lot consistency and shelf-life stability. The antigen is available in standard operator-oriented packaging fill formats of 1.0 mg and 0.2 mg, with customer-specific distinct and bulk packaging options also available.
Binding Site, 800-633-4484
Binding Site , 800-633-4484